Last night, Novavax announced the results of Phase III trials on its protein-based COVID-19 vaccine candidate showing 89.3% efficacy. The Principal Investigator on the trial is Prof Paul Heath from St George’s, University of London. The SMC invited Paul to brief science journalists about his trial, talk them through the results and answer their questions.
Prof Paul Heath, Principal Investigator of the UK arm of the Novavax vaccine trial, and Professor of Paediatric Infectious Diseases and Director of the Vaccine Institute, St George’s, University of London
SMC Rapid Reaction on Novavax announcing Phase III results for their COVID-19 vaccine candidate.